Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Product Licensing
Inovio Biomedical grants Wyeth license to develop infectious disease DNA vaccines
December 6th, 2006
Inovio Biomedical Corp. (INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced that it has granted Wyeth Pharmaceuticals, a division of Wyeth (WYE), a worldwide nonexclusive license to its DNA delivery technology for intramuscular applications of certain therapeutic DNA vaccines. Under the terms of the agreement, Inovio will receive from Wyeth a $4.5 million upfront license fee, annual license maintenance fees, research support, and up to $60 million in payments based on successful completion of clinical and regulatory milestones. Inovio would exclusively supply Wyeth with electroporation devices for the vaccines...
Source: Vaccine Weekly (2006-12-06)
|
